NewGenIvf Group Limited Class A Ordinary Shares (NIVF) - Total Liabilities
Based on the latest financial reports, NewGenIvf Group Limited Class A Ordinary Shares (NIVF) has total liabilities worth $6.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NewGenIvf Group Limited Class A Ordinary Shares - Total Liabilities Trend (2021–2024)
This chart illustrates how NewGenIvf Group Limited Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See NIVF working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
NewGenIvf Group Limited Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of NewGenIvf Group Limited Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
Germany | €18.41 Million |
|
Zephyr Energy PLC
LSE:ZPHR
|
UK | GBX34.75 Million |
|
Agronomics Ltd
LSE:ANIC
|
UK | GBX147.60K |
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
USA | $4.40 Million |
|
ENGAGE XR HLDGS EO-001
F:6VR
|
Germany | €693.16K |
|
Europejskie Centrum Odszkodowań SA
WAR:EUC
|
Poland | zł94.12 Million |
|
Vina Technology Co. Ltd.
KQ:126340
|
Korea | ₩111.85 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down NewGenIvf Group Limited Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is NewGenIvf Group Limited Class A Ordinary worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewGenIvf Group Limited Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewGenIvf Group Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual total liabilities of NewGenIvf Group Limited Class A Ordinary Shares from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.06 Million | -11.57% |
| 2023-12-31 | $5.72 Million | +132.12% |
| 2022-12-31 | $2.46 Million | +5.90% |
| 2021-12-31 | $2.33 Million | -- |
About NewGenIvf Group Limited Class A Ordinary Shares
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company's fertility treatment solutions include in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sp… Read more